Switch to:
More From Other Websites
Exelixis Up on Swiss Approval of Advanced Melanoma Drug Aug 28 2015
Did Hedge Funds Sell Out Of Exelixis, Inc. (EXEL) Too Soon? Shares Jump On Regulatory Approval of... Aug 27 2015
Exelixis (EXEL) Stock Climbs as Melanoma Treatment Gets Swiss Regulatory Approval Aug 27 2015
Exelixis Announces First Regulatory Approval of Cobimetinib in Switzerland Aug 27 2015
Exelixis Announces First Regulatory Approval of Cobimetinib in Switzerland Aug 27 2015
Exelixis' Cancer Drug Gets Breakthrough Therapy Status Aug 25 2015
EXELIXIS, INC. Financials Aug 25 2015
FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal... Aug 24 2015
Data From METEOR Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Accepted as... Aug 24 2015
Data From METEOR Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Accepted as... Aug 24 2015
FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal... Aug 24 2015
Make Room for Exelixis in Your Portfolio Aug 12 2015
Exelixis Posts Wider-Than-Expected Loss, Focus on Pipeline Aug 12 2015
Edited Transcript of EXEL earnings conference call or presentation 11-Aug-15 9:00pm GMT Aug 12 2015
Exelixis Inc Earnings Call scheduled for 5:00 pm ET today Aug 11 2015
Exelixis reports 2Q loss Aug 11 2015
Exelixis reports 2Q loss Aug 11 2015


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK